AllianceBernstein’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-74,000
| Closed | -$137K | – | 3329 |
|
|
2023
Q1 | $137K | Hold |
74,000
| – | – | ﹤0.01% | 2979 |
|
|
2022
Q4 | $82.1K | Buy |
74,000
+6,400
| +9% | +$9.11K | ﹤0.01% | 3131 |
|
|
2022
Q3 | $158K | Buy |
67,600
+2,500
| +4% | +$8.85K | ﹤0.01% | 3062 |
|
|
2022
Q2 | $197K | Buy |
65,100
+3,000
| +5% | +$14.6K | ﹤0.01% | 3031 |
|
|
2022
Q1 | $422K | Buy |
62,100
+200
| +0.3% | +$1.43K | ﹤0.01% | 2748 |
|
|
2021
Q4 | $517K | Hold |
61,900
| – | – | ﹤0.01% | 2726 |
|
|
2021
Q3 | $460K | Hold |
61,900
| – | – | ﹤0.01% | 2787 |
|
|
2021
Q2 | $421K | Buy |
61,900
+6,000
| +11% | +$49.8K | ﹤0.01% | 2887 |
|
|
2021
Q1 | $574K | Hold |
55,900
| – | – | ﹤0.01% | 2611 |
|
|
2020
Q4 | $391K | Hold |
55,900
| – | – | ﹤0.01% | 2708 |
|
|
2020
Q3 | $456K | Sell |
55,900
-600
| -1% | -$3.72K | ﹤0.01% | 2568 |
|
|
2020
Q2 | $390K | Buy |
56,500
+6,300
| +13% | +$34K | ﹤0.01% | 2758 |
|
|
2020
Q1 | $238K | Buy |
50,200
+8,100
| +19% | +$46.6K | ﹤0.01% | 2722 |
|
|
2019
Q4 | $368K | Hold |
42,100
| – | – | ﹤0.01% | 2688 |
|
|
2019
Q3 | $140K | Hold |
42,100
| – | – | ﹤0.01% | 3021 |
|
|
2019
Q2 | $208K | Buy |
42,100
+800
| +2% | +$4.25K | ﹤0.01% | 2953 |
|
|
2019
Q1 | $256K | Hold |
41,300
| – | – | ﹤0.01% | 2822 |
|
|
2018
Q4 | $139K | Hold |
41,300
| – | – | ﹤0.01% | 2948 |
|
|
2018
Q3 | $268K | Buy |
41,300
+1,600
| +4% | +$11.9K | ﹤0.01% | 2893 |
|
|
2018
Q2 | $304K | Buy |
39,700
+21,900
| +123% | +$316K | ﹤0.01% | 2811 |
|
|
2018
Q1 | $398K | Buy |
17,800
+4,200
| +31% | +$93.2K | ﹤0.01% | 2588 |
|
|
2017
Q4 | $173K | Buy |
13,600
+1,000
| +8% | +$14.7K | ﹤0.01% | 2901 |
|
|
2017
Q3 | $196K | Hold |
12,600
| – | – | ﹤0.01% | 2950 |
|
|
2017
Q2 | $177K | Buy |
+12,600
| New | +$270K | ﹤0.01% | 3018 |
|
Other funds holding JNCE
AllianceBernstein's JNCE Position: Q2 2023 in Review
AllianceBernstein sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 74,000 shares — an estimated $137K sold.
AllianceBernstein first reported a position in JNCE in Q2 2017 and held it in 24 quarters. The position peaked at $574K in Q1 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- AllianceBernstein reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- AllianceBernstein sold 74,000 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $137K.
- AllianceBernstein first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 24 quarters.
- AllianceBernstein's Jounce Therapeutics, Inc. Common Stock position peaked at $574K in Q1 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on AllianceBernstein's 13F filing for Q2 2023, filed 15 Aug 2023.